Nuvation Bio (NUVB) Current Deferred Revenue (2024 - 2026)
Nuvation Bio (NUVB) posted quarterly Current Deferred Revenue of $9.7 million for Q1 2026, up 4771.5% year-over-year from $200000.0 in Q1 2025, and up 29.65% quarter-over-quarter from $7.5 million in Q4 2025.
Nuvation Bio (NUVB) Current Deferred Revenue (2024 - 2026) Analysis & Trends
Nuvation Bio (NUVB) has reported Current Deferred Revenue for 3 consecutive years, with $9.7 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Current Deferred Revenue rose 4771.5% year-over-year to $9.7 million; the TTM figure through Mar 2026 stood at $9.7 million (up 4771.5% YoY), while the FY2025 annual figure was $7.5 million, down 51.74% from the prior year.
- Current Deferred Revenue climbed to $9.7 million in Q1 2026 per NUVB's latest filing, from $7.5 million in the prior quarter.
- Across five years, Current Deferred Revenue topped out at $15.6 million in Q4 2024 and bottomed at $200000.0 in Q1 2025.
- Historically, Current Deferred Revenue has averaged $9.2 million across 3 years, with a median of $10.4 million in 2025.
- Annual changes were most pronounced in 2025 — Current Deferred Revenue tumbled 63.11% — and 2026, when it surged 4771.5%.
- Nuvation Bio's Current Deferred Revenue stood at $15.6 million in 2024, then tumbled by 51.74% to $7.5 million in 2025, then climbed by 29.65% to $9.7 million in 2026.
- Business Quant data shows NUVB's Current Deferred Revenue at $9.7 million in Q1 2026, $7.5 million in Q4 2025, and $11.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Nuvation Bio | 2.16 Bn | 2.16 Bn | 30.78 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 8.86 Mn |
| Mar 31, 2026 | 9.74 Mn |
| Dec 31, 2025 | 7.52 Mn |
| Sep 30, 2025 | 11.13 Mn |
| Jun 30, 2025 | 4.50 Mn |
| Mar 31, 2025 | 200,000.00 |
| Dec 31, 2024 | 15.57 Mn |
| Sep 30, 2024 | 12.94 Mn |
| Jun 30, 2024 | 12.20 Mn |